For instance, a potentially paradigm-shifting exploratory study analyzed the tumor immune microenvironment of patients with mCRPC undergoing 177Lu-PSMA-617 therapy [63,66], correlating baseline tumor gene expression signatures from archival primary tumor tissue with clinical outcomes. The gene discussed is FOLH1; the disease is neoplasm.